- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04605055
The Interplay Between Oxalate, Immunity and Infection
December 8, 2023 updated by: Tanecia Mitchell, PhD, University of Alabama at Birmingham
This study consists of having subjects, those with calcium oxalate kidney stones as well as healthy controls, consume low and oxalate enriched diets to investigate the role of oxalate on crystalluria (the presence of crystals in urine), immunity and infection.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
88
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tanecia Mitchell, PhD
- Phone Number: 205-996-2292
- Email: taneciamitchell@uabmc.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Able to provide informed consent
- Body Mass Index (BMI) between 20-30 kg/m2
- Non tobacco users or not pregnant/breast feeding/nursing
- Normal fasting blood comprehensive metabolic panel, complete blood count, C-reactive protein, and urinalysis. Must accurately collect two 24-hour urine collections within 20% of appropriate ratio of creatinine (mg)/body weight (kg) for gender
- Healthy subjects: No history of calcium oxalate kidney stones (CaOx KS) or other medical conditions
- Patients with CaOx KS: Recent stone composition greater than 50% CaOx; no uric acid or struvite stone content must be present. Must be first time or recurrent CaOx stone former (last stone event within the past 3 years)
- Willing to not consume supplements (i.e. vitamins, Ca (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, and probiotics) for 2 weeks before the study and during the study
- Willing to abstain from vigorous exercise during the study as this may compromise immune function.
- Willing to consume diets provided only by the University of Alabama Center for Clinical and Translational Science Bionutrition Core. No food allergies or intolerance to any of the foods on the study menus.
- Willing to accurately collect 24-hour urine samples, and to have blood drawn throughout the study.
- If on medications for kidney stone prevention (e.g. thiazides, citrate supplementation excluding calcium citrate), patients must be on a stable dose regimen for at least 8 weeks prior to and during screening, with no changes in dosing anticipated during the study. Patients should not take allopurinol for 2 weeks prior to screening since allopurinol has anti-oxidant properties.
Exclusion Criteria:
- Failure to meet the inclusion criteria or physician refusal
- Inability to sign and read the informed consent
- Any medical, psychiatric, or social conditions that would prohibit participants from abiding to the study requirements
- BMI greater than 30 kg/m2 or less than 20 kg/m2
- Tobacco users or pregnant or breast feeding/nursing women
- Abnormal fasting blood comprehensive metabolic panel, complete blood count, C-reactive protein, and urinalysis. Inaccurate 24-hour urine collections.
- Healthy subjects: Taking medications or dietary supplements. History of kidney stones or any medical condition that could influence absorption or excretion of oxalate.
- Active illness including COVID-19, flu, common cold, fever, diarrhea, urinary tract infections or other infections 14 days before the study and throughout the study.
- Active disease including diabetes, gout, hypertension, primary hyperoxaluria, nephrotic syndrome, enteric hyperoxaluria, renal tubular acidosis, primary hyperparathyroidism, liver disease, autoimmune disorder, neurogenic bladder, urinary diversion, and bariatric surgery.
- Active malignancy or treatment for malignancy within 12 months prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Oxalate Diet Followed by High Oxalate Diet
Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet.
After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
|
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
|
Experimental: High Oxalate Diet Followed by Low Oxalate Diet
Subjects will consume a high oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet.
After the wash out period, subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
|
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary Oxalate
Time Frame: Change between Baseline and Diets at 4 days
|
Twenty-four hour urinary oxalate will be reported as mg/day
|
Change between Baseline and Diets at 4 days
|
Crystalluria
Time Frame: Change between Baseline and Diets at 4 days
|
Twenty-four hour crystalluria will be reported as particles/ml
|
Change between Baseline and Diets at 4 days
|
Monocyte Cellular Bioenergetics
Time Frame: Change between Baseline and Diets at 4 days
|
Cellular bioenergetics will be reported as oxygen consumption rate
|
Change between Baseline and Diets at 4 days
|
Monocyte Mitochondrial Complex Activity
Time Frame: Change between Baseline and Diets at 4 days
|
Monocyte mitochondrial complex activity will be reported as oxygen consumption rate
|
Change between Baseline and Diets at 4 days
|
Monocyte Transcriptomics
Time Frame: Change between Baseline and Diets at 4 days
|
Monocyte transcriptomics will be reported as gene expression (mRNA levels)
|
Change between Baseline and Diets at 4 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Tanecia Mitchell, PhD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
November 30, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
October 12, 2020
First Submitted That Met QC Criteria
October 21, 2020
First Posted (Actual)
October 27, 2020
Study Record Updates
Last Update Posted (Estimated)
December 12, 2023
Last Update Submitted That Met QC Criteria
December 8, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-300005965
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Stone
-
Washington University School of MedicineRecruiting
-
Société Internationale d'UrologieCompletedStone Ureter | Stone, Kidney | Stone;RenalUnited States, China, Korea, Republic of, Malaysia, Saudi Arabia, Greece, India, Indonesia, Iran, Islamic Republic of, Iraq, Kenya, Romania, South Africa, Taiwan, Turkey
-
Wake Forest University Health SciencesCogenix Medical CorporationWithdrawnKidney Stone | Renal Stone | Ureter StoneUnited States
-
Advance Shockwave Technology GmbHUnknownKidney StonesUnited States
-
Mansoura UniversityCompletedUrologic Diseases | Stone, Kidney | Stone, Urinary | ESWL | Radiolucent Calculus of Urinary Tract | DissolutionEgypt
-
University of British ColumbiaActive, not recruiting
-
Mansoura UniversityUnknownUrologic Diseases | Stones, Kidney | Stone, Urinary | Shock Wave LithotripsyEgypt
-
Selcuk UniversityThe Scientific and Technological Research Council of TurkeySuspendedKidney StonesTurkey
-
Mansoura UniversityCompleted
-
Alnylam PharmaceuticalsTerminatedRecurrent Calcium Oxalate Kidney Stone Disease | Elevated Urinary Oxalate LevelsUnited States, Italy, Spain, Belgium, Switzerland, United Kingdom
Clinical Trials on Low Oxalate Diet
-
University of Alabama at BirminghamNational Institutes of Health (NIH)Recruiting
-
University of Alabama at BirminghamActive, not recruiting
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingHealthy | Kidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Western Galilee Hospital-NahariyaUnknownVulvodynia | Vulvar Vestibulitis
-
University of Alabama at BirminghamUniversity of Texas Southwestern Medical CenterRecruitingKidney StoneUnited States
-
University of Alabama at BirminghamActive, not recruitingCalcium Oxalate UrolithiasisUnited States
-
University of Alabama at BirminghamRecruiting
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingKidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
University of ChicagoUniversity of Alabama at BirminghamRecruiting
-
Burke Rehabilitation HospitalCompletedStroke | Ischemic StrokeUnited States